Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.

Bone Marrow Transplant 2018 10 16;53(10):1295-1303. Epub 2018 Apr 16.

Acute Leukemia Working Party of EBMT, Paris, France.

Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Median follow-up was 32 and 60 months in MSD and MUD, respectively (p < 0.01). Compared to MSD, at 4 years, MUD recipients had lower GRFS, with higher NRM, grade III-IV acute GVHD, and extensive chronic GVHD (HR: 1.42, p < 0.01). We also performed a risk factor analyses, showing unfavorable cytogenetics (HR: 1.42, p < 0.01) and peripheral blood as stem cell source (HR: 1.22, p < 0.01) associated to lower GRFS, while this was higher with in vivo T-cell depletion (TCD, HR: 0.73, p < 0.01) and shorter time from diagnosis to HSCT (HR 0.96, p < 0.01). Different factors, modifiable or not, such as donor type, stem cell source, disease biology, and in vivo TCD, impact on GRFS and this may guide in the future transplant choices to improve morbidity and long-term quality of life.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0169-6DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
October 2018
63 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter: Alahmari_MD
November 10, 2018, 4:36 pm EST
twitter
Twitter: Alahmari_MD
April 22, 2018, 3:39 pm EST
twitter
Twitter: TerkkoLib
April 19, 2018, 1:38 am EST
twitter
Twitter: Kuro_unplugged
April 16, 2018, 5:01 am EST

Publication Analysis

Top Keywords

acute myeloid
8
refined graft-versus-host
8
myeloid leukemia
8
undergoing hsct
4
aml undergoing
4
leukemia aml
4
hsct complete
4
complete remission
4
2000 2015
4
remission 2000
4
adults acute
4
grfs 5059
4
survival morbidity
4
long-term survival
4
estimating long-term
4
hsct estimating
4
morbidity surrogate
4
surrogate hsct
4
2015 matched
4
compared grfs
4

References

(Supplied by CrossRef)
Article in Blood
ML Slovak et al.
Blood 2000
Article in N Engl J Med
L Gragert et al.
N Engl J Med 2014
Article in Best Pract Res Clin Haematol
L Hambach et al.
Best Pract Res Clin Haematol 2007
Article in Bone Marrow Transpl
M Remberger et al.
Bone Marrow Transpl 2002
Article in Blood
SJ Lee et al.
Blood 2002
Article in Biol Blood Marrow Transplant
D Weisdorf et al.
Biol Blood Marrow Transplant 2012
Article in Bone Marrow Transplant
S Kurosawa et al.
Bone Marrow Transplant 2015
Article in J Clin Oncol
N Khera et al.
J Clin Oncol 2012
Article in Blood
SG Holtan et al.
Blood 2015
Article in Bone Marrow Transplant
A Ruggeri et al.
Bone Marrow Transplant 2016
Article in Leukemia
M Aoudjhane et al.
Leukemia 2005

Similar Publications